Jonah Feldman

The phase 2/3 GOG286B reported efficacy findings and new exploratory outcomes on the combination of metformin, paclictaxel, and carboplatin in patients with advanced or recurrent endometrial cancer.

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine tumors.

The FDA approved cabozantinib for previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic and extrapancreatic neuroendocrine tumors.

A propensity-score matched cohort study found a significantly reduced risk of recurrence of bladder cancer in patients who had blue light vs white light cystoscopy.

Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.

The first patient in a trial received oral zelenirstat, a N-myristoyltransferase inhibitor, to determine its safety and tolerability in relapsed/refractory AML.

In a retrospective cohort of patients with severe chronic GVHD, combination axatilimab with other GVHD therapies led to clinical benefit.

A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal cell carcinoma.

In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.

Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.

Memorial Sloan Kettering Cancer Center physicians describe challenges in diagnosis, patient care, and the potential expansion of telehealth in this continuation of November's coverfeature.

Adverse events associated with ponatinib in CML and ALL were shown to have decreased significantly since its approval, following various risk management measures.

In a retrospective cohort of patients with central nervous system manifestations of multiple myeloma, ide-cel CAR T-cell therapy was effective.

The 48-week end points of the MANIFEST-2 study show improvements in spleen reduction, symptoms, bone marrow fibrosis, and other areas by adding pelabresib to a JAK inhibitor in myelofibrosis.

In this feature, Memorial Sloan Kettering Cancer Center physicians explain what drives the collaborative process in their multidisciplinary graft-vs-host disease clinic.

In this feature we spoke to Michael J. Morris, MD, and Benjamin Garmezy, MD, on the future of radioligand therapy in patients with prostate cancer.

The ARANOTE trial confirmed radiographical PFS benefit to adding darolutamide to androgen deprivation therapy without docetaxel in the metastatic hormone-sensitive prostate cancer setting.

Patient-reported outcomes from DESTINY-Breast06 show trastuzumab deruxtecan improved time to deterioration for pain and other subscores, with no decline in overall QOL in either arm in the HER2 low/ultralow breast cancer setting.

Pembrolizumab is the first agent showing overall survival benefit as adjuvant therapy in renal cell carcinoma, leading oncologists to adopt adjuvant therapy for many of their patients.

In a feature article incorporating Case-Based Roundtable® discussions, we look at the evolution of management for chronic graft-vs-host disease (cGVHD) following allogeneic hematopoietic cell transplantation and the impact of effective non-steroid therapies for cGVHD.

Treatment with ARV-766, an investigational proteolysis targeting chimera (PROTAC) androgen receptor degrader, led to a ≥50% PSA decline in 43% of patients with metastatic castration-resistant prostate cancer.

A retrospective cohort of patients with metastatic urothelial cancer who received prior enfortumab vedotin had low efficacy when treated with sacituzumab govitecan, with the best outcomes coming from direct sequencing the two agents.

In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.

With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.

In this feature, Targeted Oncology spoke to experts in breast cancer treatment on the trends in management of toxicity with the growing drug class of antibody-drug conjugates.

A phase 2 study has begun enrolling patients with 0 to 1 prior lines of therapy to receive the mTOR inhibitor nab-Sirolimus plus letrozole for advanced or recurrent endometrioid carcinoma.

A retrospective study of real-world patients showed that immune engager therapies had the best response and progression-free survival rates in patients with multiple myeloma who had a relapse after idecabtagene vicleucel treatment.

A retrospective study of insurance claims showed patients received ruxolitinib mainly in the second or third line for chronic graft-vs-host disease, with dose adjustment used and no difference shown in time to discontinuation between adult and pediatric patients.

Participants in virtual events discussed the key issue of whether to initiate therapy immediately or wait for test results that could show the best approach in patients with advanced lung cancer.

Oncologists at Allegheny Health Network share updates on their latest approaches for optimizing surgical and systemic treatment in patients with pancreatic cancer.